FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093397246> ?p ?o ?g. }

• W2093397246 endingPage "333" @default.
• W2093397246 startingPage "325" @default.
• W2093397246 abstract "This study sought to report the final 5-year outcomes of the ENDEAVOR IV (A Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) trial comparing the Endeavor zotarolimus-eluting stent (E-ZES) (Medtronic, Santa Rosa, California) with the Taxus paclitaxel-eluting stent (PES) (Boston Scientific, Natick, Massachusetts) in patients with single de novo coronary lesions.Primary results of the ENDEAVOR IV trial demonstrated similar clinical outcomes with E-ZES and PES. Concerns with regard to late adverse clinical events with drug-eluting stents highlight the need for long-term follow-up with these devices.Late outcomes after the use of E-ZES and PES were examined in the multicenter randomized ENDEAVOR IV trial in cumulative and landmark analyses. Assessed outcomes were related to device efficacy and patient safety.At 5 years, clinical data were available for 722 (93.4%) E-ZES patients and 718 (92.6%) PES patients. Overall rates of target lesion revascularization (7.7% vs. 8.6%, p = 0.70) and target vessel failure were similar (17.2% vs. 21.1%, p = 0.061) with E-ZES compared with PES. The incidence of cardiac death or myocardial infarction (MI) was lower with E-ZES (6.4% vs. 9.1%, p = 0.048), primarily driven by a lower rate of target vessel MI with E-ZES (2.6% vs. 6.0%, p = 0.002). Although overall definite/probable stent thrombosis rates were similar between stents (1.3% vs. 2%, p = 0.42), rates of very late stent thrombosis (0.4% vs. 1.8%, p = 0.012) and late MI events (1.3% vs. 3.5%, p = 0.008) were significantly lower with E-ZES compared with PES.These data demonstrate the durable efficacy and safety of E-ZES compared with PES for the treatment of de novo coronary lesions. Significant improvements in late safety outcomes were observed with E-ZES but should be considered hypothesis-generating, given the limited statistical power of the trial. (The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions; NCT00217269)." @default.
• W2093397246 created "2016-06-24" @default.
• W2093397246 creator A5005854434 @default.
• W2093397246 creator A5011167507 @default.
• W2093397246 creator A5017208205 @default.
• W2093397246 creator A5018788603 @default.
• W2093397246 creator A5024880771 @default.
• W2093397246 creator A5031315838 @default.
• W2093397246 creator A5041084808 @default.
• W2093397246 creator A5057352435 @default.
• W2093397246 creator A5058875978 @default.
• W2093397246 creator A5060083247 @default.
• W2093397246 creator A5065425489 @default.
• W2093397246 creator A5081743465 @default.
• W2093397246 date "2013-04-01" @default.
• W2093397246 modified "2023-10-01" @default.
• W2093397246 title "The “Final” 5-Year Follow-Up From the ENDEAVOR IV Trial Comparing a Zotarolimus-Eluting Stent With a Paclitaxel-Eluting Stent" @default.
• W2093397246 cites W120407998 @default.
• W2093397246 cites W1278305590 @default.
• W2093397246 cites W149951570 @default.
• W2093397246 cites W153704585 @default.
• W2093397246 cites W1590387607 @default.
• W2093397246 cites W1972417929 @default.
• W2093397246 cites W1976886356 @default.
• W2093397246 cites W1985483330 @default.
• W2093397246 cites W1989440763 @default.
• W2093397246 cites W1989556574 @default.
• W2093397246 cites W2022856209 @default.
• W2093397246 cites W2025649563 @default.
• W2093397246 cites W2029603191 @default.
• W2093397246 cites W2049120615 @default.
• W2093397246 cites W2078761244 @default.
• W2093397246 cites W2083630382 @default.
• W2093397246 cites W2087150869 @default.
• W2093397246 cites W2087641863 @default.
• W2093397246 cites W2110347218 @default.
• W2093397246 cites W2119470649 @default.
• W2093397246 cites W2121956076 @default.
• W2093397246 cites W2137581001 @default.
• W2093397246 cites W2145622970 @default.
• W2093397246 cites W2162162242 @default.
• W2093397246 cites W2165483605 @default.
• W2093397246 cites W2210189158 @default.
• W2093397246 cites W2613557783 @default.
• W2093397246 cites W59428541 @default.
• W2093397246 doi "https://doi.org/10.1016/j.jcin.2012.12.123" @default.
• W2093397246 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23523453" @default.
• W2093397246 hasPublicationYear "2013" @default.
• W2093397246 type Work @default.
• W2093397246 sameAs 2093397246 @default.
• W2093397246 citedByCount "71" @default.
• W2093397246 countsByYear W20933972462013 @default.
• W2093397246 countsByYear W20933972462014 @default.
• W2093397246 countsByYear W20933972462015 @default.
• W2093397246 countsByYear W20933972462016 @default.
• W2093397246 countsByYear W20933972462017 @default.
• W2093397246 countsByYear W20933972462018 @default.
• W2093397246 countsByYear W20933972462019 @default.
• W2093397246 countsByYear W20933972462020 @default.
• W2093397246 countsByYear W20933972462021 @default.
• W2093397246 countsByYear W20933972462022 @default.
• W2093397246 countsByYear W20933972462023 @default.
• W2093397246 crossrefType "journal-article" @default.
• W2093397246 hasAuthorship W2093397246A5005854434 @default.
• W2093397246 hasAuthorship W2093397246A5011167507 @default.
• W2093397246 hasAuthorship W2093397246A5017208205 @default.
• W2093397246 hasAuthorship W2093397246A5018788603 @default.
• W2093397246 hasAuthorship W2093397246A5024880771 @default.
• W2093397246 hasAuthorship W2093397246A5031315838 @default.
• W2093397246 hasAuthorship W2093397246A5041084808 @default.
• W2093397246 hasAuthorship W2093397246A5057352435 @default.
• W2093397246 hasAuthorship W2093397246A5058875978 @default.
• W2093397246 hasAuthorship W2093397246A5060083247 @default.
• W2093397246 hasAuthorship W2093397246A5065425489 @default.
• W2093397246 hasAuthorship W2093397246A5081743465 @default.
• W2093397246 hasBestOaLocation W20933972461 @default.
• W2093397246 hasConcept C121608353 @default.
• W2093397246 hasConcept C126322002 @default.
• W2093397246 hasConcept C141071460 @default.
• W2093397246 hasConcept C164705383 @default.
• W2093397246 hasConcept C168563851 @default.
• W2093397246 hasConcept C2777292972 @default.
• W2093397246 hasConcept C2777546689 @default.
• W2093397246 hasConcept C2778283817 @default.
• W2093397246 hasConcept C2778583881 @default.
• W2093397246 hasConcept C2778894183 @default.
• W2093397246 hasConcept C2780400711 @default.
• W2093397246 hasConcept C2780797203 @default.
• W2093397246 hasConcept C2781464078 @default.
• W2093397246 hasConcept C500558357 @default.
• W2093397246 hasConcept C59822182 @default.
• W2093397246 hasConcept C71924100 @default.
• W2093397246 hasConcept C86803240 @default.
• W2093397246 hasConceptScore W2093397246C121608353 @default.
• W2093397246 hasConceptScore W2093397246C126322002 @default.
• W2093397246 hasConceptScore W2093397246C141071460 @default.
• W2093397246 hasConceptScore W2093397246C164705383 @default.
• W2093397246 hasConceptScore W2093397246C168563851 @default.

• next